1.Role of phospholipase D1 in glucose-induced insulin secretion in pancreatic beta cells.
Wei na MA ; Shin Young PARK ; Joong Soo HAN
Experimental & Molecular Medicine 2010;42(6):456-464
As glucose is known to induce insulin secretion in pancreatic beta cells, this study investigated the role of a phospholipase D (PLD)-related signaling pathway in insulin secretion caused by high glucose in the pancreatic beta-cell line MIN6N8. It was found that the PLD activity and PLD1 expression were both increased by high glucose (33.3 mM) treatment. The dominant negative PLD1 inhibited glucose-induced Beta2 expression, and glucose-induced insulin secretion was blocked by treatment with 1-butanol or PLD1-siRNA. These results suggest that high glucose increased insulin secretion through a PLD1-related pathway. High glucose induced the binding of Arf6 to PLD1. Pretreatment with brefeldin A (BFA), an Arf inhibitor, decreased the PLD activity as well as the insulin secretion. Furthermore, BFA blocked the glucose-induced mTOR and p70S6K activation, while mTOR inhibition with rapamycin attenuated the glucose induced Beta2 expression and insulin secretion. Thus, when taken together, PLD1 would appear to be an important regulator of glucose-induced insulin secretion through an Arf6/PLD1/mTOR/p70S6K/Beta2 pathway in MIN6N8 cells.
ADP-Ribosylation Factors/metabolism/physiology
;
Animals
;
Basic Helix-Loop-Helix Transcription Factors/metabolism/physiology
;
Cells, Cultured
;
Gene Expression Regulation, Enzymologic/drug effects
;
Glucose/*pharmacology
;
Insulin/*secretion
;
Insulin-Secreting Cells/*drug effects/enzymology/metabolism/secretion
;
Intracellular Signaling Peptides and Proteins/metabolism/physiology
;
Mice
;
Models, Biological
;
Oligodeoxyribonucleotides, Antisense/pharmacology
;
Phospholipase D/antagonists & inhibitors/genetics/metabolism/*physiology
;
Protein-Serine-Threonine Kinases/metabolism/physiology
;
Ribosomal Protein S6 Kinases, 70-kDa/metabolism/physiology
;
Signal Transduction/drug effects/genetics
2.The effects of compound CX09040 on the inhibition of PTP1B and protection of pancreatic β cells.
Ran-qi TANG ; Xiao-lin ZHANG ; Jin-ying TIAN ; Si-ming KONG ; Ying ZHOU ; Pei ZHANG ; Hong-kun YANG ; Song WU ; Ying ZHANG ; Fei YE
Acta Pharmaceutica Sinica 2015;50(6):682-689
To investigate the effects of 2-(4-methoxycarbonyl-2-tetradecyloxyphenyl)carbamoylbenzoic acid (CX09040) on protecting pancreatic β cells, the β cell dysfunction model mice were induced by injection of alloxan into the caudal vein of ICR mice, and were treated with compound CX09040. Liraglutide was used as the positive control drug. The amount and the size of islets observed in pathological sections were calculated to evaluate the β cell mass; the glucose stimulated insulin secretion (GSIS) test was applied to estimate the β cell secretary function; the oral glucose tolerance test (OGTT) was taken to observe the glucose metabolism in mice; the expressions of protein in pancreas were detected by Western blotting. The effects on the target protein tyrosine phosphatase 1B (PTP1B) were assessed by the PTP1B activities of both recombinant protein and the intracellular enzyme, and by the PTP1B expression in the pancreas of mice, separately. As the results, with the treatment of CX09040 in alloxan-induced β cell dysfunction mice, the islet amount (P<0.05) and size (P<0.05) increased significantly, the changes of serum insulin in GSIS (P<0.01) and the values of acute insulin response (AIR, P<0.01) were enhanced, compared to those in model group; the impaired glucose tolerance was also ameliorated by CX09040 with the decrease of the values of area under curve (AUC, P<0.01). The activation of the signaling pathways related to β cell proliferation was enhanced by increasing the levels of p-Akt/Akt (P<0.01), p-FoxO1/FoxOl (P<0.001) and PDX-1 (P<0.01). The effects of CX09040 on PTP1B were observed by inhibiting the recombinant hPTP1B activity with IC50 value of 2.78x 10(-7) mol.L-1, reducing the intracellular PTP1B activity of 72.8% (P<0.001), suppressing the PTP1B expression (P<0.001) and up-regulating p-IRβ/IRβ (P<0.01) in pancreas of the β cell dysfunction mice, separately. In conclusion, compound CX09040 showed significant protection effects against the dysfunction of β cell of mice by enlarging the pancreatic β cell mass and increasing the glucose-induced insulin secretion; its major mechanism may be the inhibition on target PTP1B and the succedent up-regulation of β cell proliferation.
Alloxan
;
Animals
;
Benzoates
;
pharmacology
;
Biological Assay
;
Disease Models, Animal
;
Glucose
;
metabolism
;
Glucose Tolerance Test
;
Insulin
;
secretion
;
Insulin Resistance
;
Insulin-Secreting Cells
;
drug effects
;
Liraglutide
;
pharmacology
;
Mice
;
Mice, Inbred ICR
;
Molecular Weight
;
Pancreas
;
drug effects
;
enzymology
;
Protein Tyrosine Phosphatase, Non-Receptor Type 1
;
antagonists & inhibitors
;
Signal Transduction
3.Coptidis rhizoma extract protects against cytokine-induced death of pancreatic beta-cells through suppression of NF-kappa B activation.
Eun Kyung KIM ; Kang Beom KWON ; Mi Jeong HAN ; Mi Young SONG ; Ji Hyun LEE ; Na LV ; Sun O KA ; Seung Ryong YEOM ; Young Dal KWON ; Do Gon RYU ; Kang San KIM ; Jin Woo PARK ; Raekil PARK ; Byung Hyun PARK
Experimental & Molecular Medicine 2007;39(2):149-159
We demonstrated previously that Coptidis rhizoma extract (CRE) prevented S-nitroso-N-acetylpenicillamine-induced apoptotic cell death via the inhibition of mitochondrial membrane potential disruption and cytochrome c release in RINm5F (RIN) rat insulinoma cells. In this study, the preventive effects of CRE against cytokine-induced beta-cell death was assessed. Cytokines generated by immune cells infiltrating pancreatic islets are crucial mediators of beta-cell destruction in insulin-dependent diabetes mellitus. The treatment of RIN cells with IL-1beta and IFN-gamma resulted in a reduction of cell viability. CRE completely protected IL-1beta and IFN-gamma-mediated cell death in a concentration-dependent manner. Incubation with CRE induced a significant suppression of IL-1beta and IFN-gamma-induced nitric oxide (NO) production, a finding which correlated well with reduced levels of the iNOS mRNA and protein. The molecular mechanism by which CRE inhibited iNOS gene expression appeared to involve the inhibition of NF-kappa B activation. The IL-1beta and IFN-gamma-stimulated RIN cells showed increases in NF-kappa B binding activity and p65 subunit levels in nucleus, and IkappaBalpha degradation in cytosol compared to unstimulated cells. Furthermore, the protective effects of CRE were verified via the observation of reduced NO generation and iNOS expression, and normal insulin-secretion responses to glucose in IL-1beta and IFN-gamma-treated islets.
Animals
;
Cell Death/drug effects
;
Cell Line
;
Cell Nucleus/metabolism
;
Cell Survival/drug effects
;
Drugs, Chinese Herbal/*pharmacology
;
Gene Expression Regulation, Enzymologic/drug effects
;
Glucose/pharmacology
;
I-kappa B Proteins/metabolism
;
Insulin/secretion
;
Insulin-Secreting Cells/*cytology/*drug effects/enzymology
;
Interferon-gamma/*pharmacology
;
Interleukin-1beta/*pharmacology
;
Male
;
NF-kappa B/*metabolism
;
Nitric Oxide/biosynthesis
;
Nitric Oxide Synthase Type II/genetics/metabolism
;
Protein Transport/drug effects
;
RNA, Messenger/genetics/metabolism
;
Rats
;
Rats, Sprague-Dawley